about
Characterization of monoclonal anti-beta2-glycoprotein-I and anti-prothrombin antibody fragments generated by phage display from a patient with primary antiphospholipid syndrome.Potential additional effect of omentectomy on metabolic syndrome, acute-phase reactants, and inflammatory mediators in grade III obese patients undergoing laparoscopic Roux-en-Y gastric bypass: a randomized trialThe Role of High Mobility Group Box 1 Protein (HMGB1) in the Immunopathology of Experimental Pulmonary Tuberculosis.Autoimmune comorbidity in achalasia patients.The role of β2-glycoprotein I (β2GPI) carbohydrate chains in the reactivity of anti-β2GPI antibodies from patients with primary antiphospholipid syndrome and in the activation and differentiation of U937 cells.Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome.Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome.Correction: The Role of High Mobility Group Box 1 Protein (HMGB1) in the Immunopathology of Experimental Pulmonary Tuberculosis.Refractory ascites in systemic lupus erythematosus: further biological support of intraperitoneal steroid treatment as a suitable therapeutical option.Cellular immune response to β2-glycoprotein-I valine/leucine247 phenotypes in Mexican patients with primary antiphospholipid syndrome.Chemokine saliva levels in patients with primary Sjögren's syndrome, associated Sjögren's syndrome, pre-clinical Sjögren's syndrome and systemic autoimmune diseases[Immunological Techniques that Support the Diagnosis of the Autoimmune Diseases][Citrullinated proteins in rheumatoid arthritis]The amount of citrullinated proteins in synovial tissue is related to serum anti-cyclic citrullinated peptide (anti-CCP) antibody levelsElastographic ultrasound: an additional image tool in Sjögren's syndromePrevalence and associations of anti-phosphatidylserine/prothrombin antibodies with clinical phenotypes in patients with primary antiphospholipid syndrome: aPS/PT antibodies in primary antiphospholipid syndrome
P50
Q33228597-AAEE8FDE-4F80-4BCA-B236-5FF89ED84545Q33932584-FEB2DAF7-695E-4CF5-A5AF-43DE2CFE8846Q35705833-7C406169-EB28-44A4-A872-C6C786953BBBQ38751905-4C0844FE-1094-4A0C-95E1-49E630935BA0Q38953276-3E7D1FC4-718F-49F2-9921-0362042BCD3CQ39586997-56D46567-5148-4183-A0EF-692CFB4BAB0DQ41818166-738717C0-AFCE-40FC-A157-EF56736D522EQ42921197-0A8D4214-44EF-47D7-9B42-A065C459A2F8Q51070322-90A0181F-7405-4088-9C7D-7D3B43BDFBBDQ51225645-70D3EB1B-532F-4A89-952D-7E9DDFB136E3Q83433378-73D8ABD5-1CD2-45DA-8805-A9A74A27A71EQ84601301-8ABCDBD9-D144-48C4-AB15-0994E2995F75Q84601558-FD5E9B40-D10E-47D2-B018-94B3D51874D1Q85857557-9C596BFA-799D-45C1-9A40-6550B4BA4564Q88292459-32194C9C-8894-42F0-AD23-1A0A5BEB6CC6Q90904601-0F3031FD-2FED-459C-B034-A73D80EC2386
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Diego F Hernández-Ramírez
@en
Diego F Hernández-Ramírez
@nl
type
label
Diego F Hernández-Ramírez
@en
Diego F Hernández-Ramírez
@nl
prefLabel
Diego F Hernández-Ramírez
@en
Diego F Hernández-Ramírez
@nl
P31
P496
0000-0001-7293-2278